New insider activity at Johnson & Johnson ( (JNJ) ) has taken place on July 18, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
John C. Reed, EVP of Innovative Medicine and R&D at Johnson & Johnson, has recently sold 19,137 shares of the company’s stock. This transaction was valued at a substantial $3,129,664.
Recent Updates on JNJ stock
Johnson & Johnson recently reported a strong Q2 financial performance, with a 5.8% increase in worldwide sales driven by growth in its Innovative Medicine and MedTech segments. The company raised its full-year sales and earnings per share guidance, reflecting confidence in its strategic initiatives and robust pipeline. Notably, the oncology and MedTech cardiovascular segments showed impressive growth, with operational sales increases of 22.3% and over 22%, respectively. However, challenges such as the loss of exclusivity for STELARA and declines in the orthopedics segment were acknowledged. Despite these hurdles, Johnson & Johnson’s strategic focus on innovation and market expansion positions it well for future growth.
Spark’s Take on JNJ Stock
According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.
Johnson & Johnson’s solid financial performance and strategic focus on innovation drive its strong position. However, mixed technical trends and recent legal challenges introduce some caution. The company’s stable valuation and dividend policy support a favorable long-term view.
To see Spark’s full report on JNJ stock, click here.
More about Johnson & Johnson
YTD Price Performance: 14.57%
Average Trading Volume: 8,151,375
Technical Sentiment Signal: Buy
Current Market Cap: $396.5B